• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Vertex Pharmaceuticals

edit

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company’s strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex’s product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain

Recent Milestones

edit

• 
  Vertex Pharmaceuticals — Vertex awards $1.5M to help Hepatitis C patients (11/4/11)
  Posted 11/4/11 at 7:00pm via masshightech.com
• 
  Vertex Pharmaceuticals added Dhaval Rathod as Sr Scientific associate. (6/1/11)
  Posted 11/14/11 at 11:31am
• 
  Vertex Pharmaceuticals — has won approval from the U.S. Food and Drug Administration for its hepatitis C drug, Incivek. (5/23/11)
  Posted 5/24/11 at 5:33am via masshightech.com
• 
  Vertex Pharmaceuticals — signed a lease to move to Fan Pier on the South Boston waterfront, from Cambridge (5/5/11)
  Posted 5/5/11 at 8:59am via masshightech.com
• 
  Vertex Pharmaceuticals — Vertex forms $75M deal with CFF (4/7/11)
  Posted 4/7/11 at 8:56pm via masshightech.com
• 
  Vertex Pharmaceuticals — plans to move to Fan Pier on the South Boston waterfront (1/24/11)
  Posted 1/25/11 at 4:21am via masshightech.com
• 
  Vertex Pharmaceuticals — has won priority review from the U.S. Food and Drug Administration for its hepatitis C virus treatment, telaprevir (1/20/11)
  Posted 1/24/11 at 7:11am via masshightech.com
• 
  Vertex Pharmaceuticals — has begun a Phase 2a clinical trial of a cystic fibrosis treatment that combines two of the company’s regimens (10/18/10)
  Posted 10/20/10 at 2:53am via masshightech.com
• 
  Vertex Pharmaceuticals — Vertex Pharmaceuticals Inc. said it plans to raise funds by selling $375 million worth of senior subordinated notes due 2015. (9/23/10)
  Posted 9/23/10 at 8:19am via masshightech.com
• 
  Vertex Pharmaceuticals received $443M in Post IPO Equity funding. (12/3/09)
  Posted 12/3/09 at 6:16pm via fiercebiotech.com
• 
  Vertex Pharmaceuticals received $35M in Post IPO Equity funding. (9/30/09)
  Posted 10/11/09 at 10:56pm via vrtx.com
• 
  Vertex Pharmaceuticals received $120M in Post IPO Debt funding. (9/30/09)
  Posted 8/13/10 at 3:25pm via vrtx.com
• 
  Went public with stock symbol NASDAQ:VRTX. (8/2/91)
  Posted 11/4/11 at 6:59pm
• 
  Vertex Pharmaceuticals added Larry Bock as Co-Founder.
  Posted 8/30/10 at 1:32pm
• 
  Vertex Pharmaceuticals added Matthew W. Emmens as Chairman, President and CEO.
  Posted 12/15/11 at 8:21pm
• 
  Vertex Pharmaceuticals added Ian F. Smith as Executive Vice President & CFO.
  Posted 12/15/11 at 8:21pm

Videos

Screenshots

edit

Above: Vertex Pharmaceuticals
Uploaded: 10/12/09

Stock Price

Sources

1. Vertex Pharmaceuticals to Receive $155 Million in Cash Related to Future Telaprevir Milestone Payments (investors.vrtx.com) [edit]
2. Vertex Pharmaceuticals to Receive $155 Million in Cash Related to Future Telaprevir Milestone Payments (investors.vrtx.com) [edit]
3. Vertex adds $443M to its big cash stash (fiercebiotech.com) [edit]
Vertex Pharmaceuticals raising $375M in notes sale (masshightech.com) [edit]
Vertex cystic fibrosis treatment trial begins (masshightech.com) [edit]
Vertex hepatitis C drug wins FDA priority review (masshightech.com) [edit]
Vertex moving to Boston's Fan Pier (masshightech.com) [edit]
Vertex forms $75M deal with CFF (masshightech.com) [edit]
Vertex signs lease for South Boston move (masshightech.com) [edit]
Vertex hepatitis C drug gets FDA OK (masshightech.com) [edit]
Vertex awards $1.5M to help Hepatitis C patients (masshightech.com) [edit]